image
Healthcare - Medical - Devices - NASDAQ - US
$ 11.24
0.988 %
$ 912 M
Market Cap
-18.43
P/E
1. INTRINSIC VALUE

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function.[ Read More ]

The intrinsic value of one BVS stock under the base case scenario is HIDDEN Compared to the current market price of 11.2 USD, Bioventus Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BVS

image
FINANCIALS
512 M REVENUE
0.04%
-81.7 M OPERATING INCOME
-129.08%
-96.7 M NET INCOME
54.67%
15.3 M OPERATING CASH FLOW
213.35%
15.8 M INVESTING CASH FLOW
113.58%
-26.7 M FINANCING CASH FLOW
-42.94%
139 M REVENUE
-8.10%
4.07 M OPERATING INCOME
-27.86%
-15 M NET INCOME
37.68%
11.5 M OPERATING CASH FLOW
-24.18%
-64 K INVESTING CASH FLOW
16.88%
362 K FINANCING CASH FLOW
104.61%
Balance Sheet Decomposition Bioventus Inc.
image
Current Assets 268 M
Cash & Short-Term Investments 37 M
Receivables 123 M
Other Current Assets 108 M
Non-Current Assets 543 M
Long-Term Investments 0
PP&E 50 M
Other Non-Current Assets 493 M
Current Liabilities 175 M
Accounts Payable 23 M
Short-Term Debt 32.7 M
Other Current Liabilities 120 M
Non-Current Liabilities 414 M
Long-Term Debt 378 M
Other Non-Current Liabilities 36.7 M
EFFICIENCY
Earnings Waterfall Bioventus Inc.
image
Revenue 512 M
Cost Of Revenue 184 M
Gross Profit 328 M
Operating Expenses 410 M
Operating Income -81.7 M
Other Expenses 15 M
Net Income -96.7 M
RATIOS
64.06% GROSS MARGIN
64.06%
-15.95% OPERATING MARGIN
-15.95%
-30.49% NET MARGIN
-30.49%
-90.00% ROE
-90.00%
-19.27% ROA
-19.27%
-14.39% ROIC
-14.39%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bioventus Inc.
image
Net Income -96.7 M
Depreciation & Amortization 57.4 M
Capital Expenditures -7.36 M
Stock-Based Compensation 2.72 M
Change in Working Capital -3.18 M
Others 44.3 M
Free Cash Flow 7.98 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bioventus Inc.
image
Wall Street analysts predict an average 1-year price target for BVS of $10.2 , with forecasts ranging from a low of $8 to a high of $12 .
BVS Lowest Price Target Wall Street Target
8 USD -28.83%
BVS Average Price Target Wall Street Target
10.2 USD -8.81%
BVS Highest Price Target Wall Street Target
12 USD 6.76%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Bioventus Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
296 K USD 3
6-9 MONTHS
93.4 K USD 3
9-12 MONTHS
0 USD 0
Bought
218 K USD 1
0-3 MONTHS
684 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Aug 19, 2024
Bought 218 K USD
Bartholdson John A.
director, 10 percent owner:
+ 25500
8.5477 USD
3 months ago
Aug 16, 2024
Bought 684 K USD
Bartholdson John A.
director, 10 percent owner:
+ 80000
8.5467 USD
4 months ago
Jun 21, 2024
Sell 51.3 K USD
Singleton Mark Leonard
SVP & CFO
- 9219
5.57 USD
4 months ago
Jun 21, 2024
Sell 32.9 K USD
D'Adamio Anthony
SVP & General Counsel
- 5904
5.57 USD
4 months ago
Jun 21, 2024
Sell 14.3 K USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 2559
5.57 USD
5 months ago
Jun 17, 2024
Sell 80.3 K USD
Singleton Mark Leonard
SVP & CFO
- 13753
5.84 USD
5 months ago
Jun 17, 2024
Sell 66 K USD
D'Adamio Anthony
SVP & General Counsel
- 11308
5.84 USD
5 months ago
Jun 17, 2024
Sell 51.2 K USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 8759
5.84 USD
7 months ago
Apr 11, 2024
Sell 19 K USD
Singleton Mark Leonard
SVP & CFO
- 4000
4.75 USD
7 months ago
Apr 11, 2024
Sell 14.5 K USD
D'Adamio Anthony
SVP & General Counsel
- 3054
4.75 USD
7 months ago
Apr 11, 2024
Sell 6.29 K USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 1325
4.75 USD
7 months ago
Mar 22, 2024
Sell 29.9 K USD
Singleton Mark Leonard
SVP & CFO
- 5541
5.3876 USD
8 months ago
Mar 15, 2024
Sell 17.1 K USD
D'Adamio Anthony
SVP & General Counsel
- 3125
5.46 USD
8 months ago
Mar 15, 2024
Sell 6.64 K USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 1217
5.46 USD
1 year ago
Aug 18, 2023
Bought 55 K USD
Bihl Anthony P III
Interim CEO
+ 13290
4.1388 USD
1 year ago
Aug 18, 2023
Bought 110 K USD
Bihl Anthony P III
Interim CEO
+ 26595
4.1388 USD
1 year ago
Aug 14, 2023
Bought 71.8 K USD
Bartholdson John A.
director, 10 percent owner:
+ 14985
4.7883 USD
1 year ago
Aug 11, 2023
Bought 230 K USD
Bartholdson John A.
director, 10 percent owner:
+ 50037
4.5953 USD
1 year ago
Aug 14, 2023
Bought 71.8 K USD
Juniper Investment Company, LLC
10 percent owner
+ 14985
4.79 USD
1 year ago
Aug 11, 2023
Bought 228 K USD
Juniper Investment Company, LLC
10 percent owner
+ 50037
4.56 USD
1 year ago
Aug 10, 2023
Bought 500 K USD
Juniper Investment Company, LLC
10 percent owner
+ 111848
4.47 USD
1 year ago
Aug 10, 2023
Bought 500 K USD
Bartholdson John A.
director, 10 percent owner:
+ 111848
4.4741 USD
1 year ago
Jul 03, 2023
Sell 1.12 K USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 394
2.83 USD
1 year ago
Jun 15, 2023
Bought 398 K USD
Bartholdson John A.
director, 10 percent owner:
+ 110180
3.6092 USD
1 year ago
Jun 14, 2023
Bought 590 K USD
Bartholdson John A.
director, 10 percent owner:
+ 181946
3.2401 USD
1 year ago
Jun 13, 2023
Bought 184 K USD
Bartholdson John A.
director, 10 percent owner:
+ 60324
3.0487 USD
1 year ago
Jun 12, 2023
Bought 1.15 M USD
Bartholdson John A.
director, 10 percent owner:
+ 395401
2.9192 USD
2 years ago
Apr 01, 2022
Sell 211 USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 15
14.07 USD
2 years ago
Jul 01, 2022
Sell 390 USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 58
6.73 USD
2 years ago
Oct 03, 2022
Sell 406 USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 58
7 USD
1 year ago
May 25, 2023
Bought 117 K USD
HAWKINS WILLIAM A
Director
+ 44000
2.6631 USD
1 year ago
May 24, 2023
Bought 118 K USD
HAWKINS WILLIAM A
Director
+ 44000
2.6907 USD
1 year ago
May 23, 2023
Bought 291 K USD
Bihl Anthony P III
Interim CEO
+ 125000
2.3279 USD
1 year ago
May 22, 2023
Bought 372 K USD
Bartholdson John A.
Director
+ 178998
2.0799 USD
1 year ago
May 19, 2023
Bought 2.2 M USD
Bartholdson John A.
Director
+ 1136675
1.9362 USD
2 years ago
Apr 01, 2022
Sell 563 USD
Nosenzo John
Fmr. Chief Commercial Officer
- 40
14.07 USD
2 years ago
Jul 01, 2022
Sell 639 USD
Nosenzo John
Fmr. Chief Commercial Officer
- 95
6.73 USD
2 years ago
Oct 03, 2022
Sell 49 USD
Nosenzo John
Fmr. Chief Commercial Officer
- 7
7 USD
2 years ago
Apr 01, 2022
Sell 211 USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 15
14.07 USD
2 years ago
Jul 01, 2022
Sell 390 USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 58
6.73 USD
2 years ago
Oct 03, 2022
Sell 406 USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 58
7 USD
1 year ago
Apr 03, 2023
Sell 125 USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 117
1.07 USD
1 year ago
Mar 24, 2023
Sell 7.68 K USD
Singleton Mark Leonard
SVP & CFO
- 6044
1.27 USD
1 year ago
Mar 15, 2023
Sell 4.74 K USD
D'Adamio Anthony
SVP & General Counsel
- 3409
1.3897 USD
1 year ago
Mar 15, 2023
Sell 13.6 K USD
Reali Kenneth Michael
Chief Executive Officer
- 9811
1.3887 USD
1 year ago
Mar 15, 2023
Sell 1.85 K USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
- 1332
1.3886 USD
2 years ago
Apr 01, 2022
Sell 179 K USD
D'Adamio Anthony
SVP & General Counsel
- 16016
11.1912 USD
2 years ago
Apr 01, 2022
Sell 734 K USD
Nosenzo John
Chief Commercial Officer
- 65963
11.1199 USD
2 years ago
Apr 01, 2022
Sell 368 K USD
Pavesio Alessandra
SVP & Chief Science Officer
- 32997
11.1654 USD
2 years ago
Feb 14, 2022
Sell 5.19 K USD
Pavesio Alessandra
SVP & Chief Science Officer
- 433
11.99 USD
2 years ago
Feb 14, 2022
Sell 15.5 K USD
D'Adamio Anthony
SVP & General Counsel
- 1294
11.9883 USD
2 years ago
Feb 14, 2022
Sell 15.5 K USD
Anglum Gregory O.
SVP & CFO
- 1294
11.9924 USD
2 years ago
Feb 14, 2022
Sell 6.4 K USD
Nosenzo John
Chief Commercial Officer
- 534
11.9875 USD
3 years ago
Sep 09, 2021
Bought 26.7 K USD
Reali Kenneth Michael
CHIEF EXECUTIVE OFFICER
+ 1800
14.81 USD
3 years ago
Feb 11, 2021
Bought 13 K USD
Pavesio Alessandra
SVP & Chief Science Officer
+ 1000
13 USD
3 years ago
Feb 11, 2021
Bought 13 K USD
D'Adamio Anthony
SVP & General Counsel
+ 1000
13 USD
3 years ago
Feb 11, 2021
Bought 78 K USD
Anglum Gregory O.
SVP & General Counsel
+ 6000
13 USD
3 years ago
Feb 11, 2021
Bought 122 K USD
Reali Kenneth Michael
Chief Executive Officer
+ 9375
13 USD
3 years ago
Feb 11, 2021
Bought 6.5 K USD
Nosenzo John
Chief Commercial Officer
+ 500
13 USD
3 years ago
Feb 11, 2021
Bought 32.5 K USD
CHURCH KATRINA J
SVP & Chief Compliance Officer
+ 2500
13 USD
7. News
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript Bioventus Inc. (NASDAQ:BVS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President and CEO Mark Singleton - Senior Vice President and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Robbie Marcus - J.P. Morgan Caitlin Cronin - Canaccord Genuity Operator Good day, and welcome to the Bioventus Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 1 week ago
Bioventus (BVS) Matches Q3 Earnings Estimates Bioventus (BVS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago. zacks.com - 1 week ago
Bioventus Reports Third Quarter Financial Results DURHAM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024. globenewswire.com - 1 week ago
Are Medical Stocks Lagging Bioventus (BVS) This Year? Here is how Bioventus (BVS) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year. zacks.com - 1 week ago
Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings? Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results. zacks.com - 2 weeks ago
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024 DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. globenewswire.com - 2 weeks ago
Bioventus Surges 73% in Three Months: Time to Buy the Stock? BVS generates encouraging returns, driven by rapid sales growth across the Pain Treatments and Surgical Solutions franchises. zacks.com - 3 weeks ago
First September Gains in 5 Years? Buy 3 Breakout Stocks Now Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today. zacks.com - 1 month ago
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy? BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises. zacks.com - 1 month ago
Bull Of The Day: Bioventus (BVS) This stock has seen 3 consecutive beats of the Zacks Consensus Estimate and also posted solid margin expansion. zacks.com - 2 months ago
Executives Buying W. P. Carey And 2 Other Stocks Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. benzinga.com - 2 months ago
5 Small Drug Stocks to Buy as Innovation Reaches Peak Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio. zacks.com - 3 months ago
8. Profile Summary

Bioventus Inc. BVS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 912 M
Dividend Yield 0.00%
Description Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Contact 4721 Emperor Boulevard, Durham, NC, 27703 https://www.bioventus.com
IPO Date Feb. 11, 2021
Employees 1030
Officers Mr. Mike Crowe B.S., M.B.A. Senior Vice President of Operations Mr. Robert E. Claypoole President, Chief Executive Officer & Director Ms. Katrina J. Church J.D. Senior Vice President & Chief Compliance Officer Ms. Helen Leupold Senior Vice President & Chief Human Resources Officer Mr. Mark L. Singleton Senior Vice President & Chief Financial Officer Mr. David Crawford Vice President of Investor Relations & Treasurer Mr. Larry Chen Managing Director of China & Asia Pacific